Production (Stage)
Hemostemix Inc.
HMTXF
$0.0917
$0.00465.28%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 679.60K | 200.60K | 264.00K | 238.90K | 421.00K |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 679.60K | 200.60K | 264.00K | 241.10K | 340.30K |
| Operating Income | -679.60K | -200.60K | -264.00K | -241.10K | -340.30K |
| Income Before Tax | -933.70K | -230.60K | -379.50K | -352.70K | -502.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -933.70K | -230.60K | -379.50K | -352.70K | -502.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -933.70K | -230.60K | -379.50K | -352.70K | -502.50K |
| EBIT | -679.60K | -200.60K | -264.00K | -241.10K | -340.30K |
| EBITDA | -679.60K | -200.60K | -264.00K | -241.10K | -340.20K |
| EPS Basic | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 118.87M | 87.12M | 87.12M | 87.12M | 98.73M |
| Average Diluted Shares Outstanding | 118.87M | 87.12M | 87.12M | 87.12M | 98.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |